- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Early EU Experience Shows Positive Results for Samsung Bioepis' Biosimilar Adalimumab
The launch of biosimilar adalimumab products in the European Union in October 2018 was an important moment for health systems in serious need of cost savings on one of their top drugs for spending: Humira. Now, early data show that adalimumab biosimilars are off to a strong start in the EU market.
The launch of biosimilar adalimumab products in the European Union in October 2018 was an important moment for health systems in serious need of cost savings on one of their top drugs for spending: Humira. Now, early data reported by IQVIA show that adalimumab biosimilars are off to a strong start in the EU market.
According to IQVIA’s data, 14 countries had biosimilar adalimumab available as of November 2018: the United Kingdom, Germany, France, Spain, Italy, the Netherlands, Belgium, Sweden, Ireland, Austria, Finland, Denmark, the Czech Republic, and Slovenia. Among these nations, Germany had the most biosimilar options available, with launches of Samsung Bioepis’ Imraldi, Amgen’s Amgevita, Sandoz’s Hyrimoz, and Mylan’s Hulio. Austria and Finland, by contrast, each had just 1 biosimilar available: Amgevita.
In Germany, the number of patients taking the brand-name Humira fell in November versus the year before biosimilars launched. While some patients were switched to other agents, such as the interleukin inhibitors sekukinumab (Cosentyx) or ustekinumab (Stelara) that are often used as alternatives for patients who lose response to anti—tumor necrosis factor therapies, the greatest percentages of patients who switched away from Humira were transitioned to Imraldi (37%), Hyrimoz (15%), and Amgevita (12%).
In the United Kingdom, which was responsible for the most consumption of brand-name Humira in the European Union as of September 2018, a centralized tender broke the adalimumab market into 11 regions, and awarded shares of the market to multiple bidders. Imraldi took the greatest share, with nearly 45% of the English market. Amgevita and Sandoz were each awarded roughly one-fourth of the market, and Hulio was awarded approximately 5% of the market.
According to IQVIA, “It is Samsung with Imraldi that has won out so far in the 2 markets that matter the most: Samsung has the largest potential market in the United Kingdom and has shown the most success in acquiring Humira patients in Germany.”
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
